HUP0203837A2 - Testtömegnövekedést gátló szerek - Google Patents

Testtömegnövekedést gátló szerek

Info

Publication number
HUP0203837A2
HUP0203837A2 HU0203837A HUP0203837A HUP0203837A2 HU P0203837 A2 HUP0203837 A2 HU P0203837A2 HU 0203837 A HU0203837 A HU 0203837A HU P0203837 A HUP0203837 A HU P0203837A HU P0203837 A2 HUP0203837 A2 HU P0203837A2
Authority
HU
Hungary
Prior art keywords
body weight
weight gain
subject
substance
agonist
Prior art date
Application number
HU0203837A
Other languages
English (en)
Inventor
Hiroyuki Kimura
Hiroyuki Odaka
Yasuo Sugiyama
Original Assignee
Takeda Chemical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.
Publication of HUP0203837A2 publication Critical patent/HUP0203837A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Abstract

A találmány tárgya PPAR agonista anyagokkal való kezelésből eredőtesttömeg-növekedés csökkentésére alkalmazható szer, amely PPARdagonista anyagot tartalmaz. A találmány tárgyát képező szer diabéteszkezelésére alkalmazható. A találmány tárgyát képezik az olyan szerekis, amelyekben a PPARd agonista anyag PPARg agonista hatással isrendelkezik. Ó
HU0203837A 1999-11-10 2000-11-09 Testtömegnövekedést gátló szerek HUP0203837A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP32031999 1999-11-10
PCT/JP2000/007879 WO2001034200A1 (fr) 1999-11-10 2000-11-09 Inhibiteurs de prise de poids

Publications (1)

Publication Number Publication Date
HUP0203837A2 true HUP0203837A2 (hu) 2003-03-28

Family

ID=18120170

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203837A HUP0203837A2 (hu) 1999-11-10 2000-11-09 Testtömegnövekedést gátló szerek

Country Status (10)

Country Link
US (1) US20050239854A1 (hu)
EP (1) EP1304121A4 (hu)
KR (1) KR20020060227A (hu)
CN (1) CN1423566A (hu)
AU (1) AU1303301A (hu)
CA (1) CA2390932A1 (hu)
HU (1) HUP0203837A2 (hu)
NO (1) NO20022214L (hu)
PL (1) PL356745A1 (hu)
WO (1) WO2001034200A1 (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1303201A (en) * 1999-11-10 2001-06-06 Takeda Chemical Industries Ltd. Alkoxyiminoalkanoic acid derivatives
CA2403903A1 (en) * 2000-03-28 2002-09-26 Masatoshi Hazama Angiogenesis inhibitors
AU2002243778A1 (en) * 2001-02-02 2002-09-19 Smithkline Beecham Corporation Treatment of ppar mediated diseases
US20040077689A1 (en) * 2001-04-25 2004-04-22 Yasuo Sugiyama Abc expression promoters
EP2022505B1 (en) 2001-07-31 2011-12-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services GLP-1, exendin-4, peptide analogs and uses thereof
WO2003082865A1 (fr) * 2002-04-01 2003-10-09 Sankyo Company, Limited Composition médicinale antitumorale
ATE551056T1 (de) 2002-12-27 2012-04-15 Takeda Pharmaceutical Mittel zur hemmung der körpergewichtszunahme
WO2005105726A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
JP4981662B2 (ja) 2004-05-05 2012-07-25 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 新規の化合物、その製法と使用
WO2007003581A1 (en) 2005-06-30 2007-01-11 Novo Nordisk A/S Phenoxy acetic acids as ppar delta activators
EP1939189A4 (en) * 2005-08-26 2013-03-13 Shionogi & Co DERIVATIVE HAVING AGONIST ACTIVITY AGAINST PPAR
US7943613B2 (en) 2005-12-22 2011-05-17 High Point Pharmaceuticals, Llc Compounds, their preparation and use
CA2645719A1 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
US20110230428A1 (en) * 2008-07-22 2011-09-22 John Wityak Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
DK3241558T3 (da) 2010-09-28 2021-04-26 Aegerion Pharmaceuticals Inc Højopløselige leptiner
EP3243515B1 (en) 2011-08-30 2019-10-16 CHDI Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2013033068A1 (en) 2011-08-30 2013-03-07 Stephen Martin Courtney Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP3756661A1 (en) 2013-09-09 2020-12-30 vTv Therapeutics LLC Use of a ppar-delta agonist for treating muscle atrophy
EP3169684B1 (en) 2014-07-17 2019-06-26 CHDI Foundation, Inc. Combination of kmo inhibitor 6-(3-chloro-4-cyclopropoxyphenyl)pyrimidine-4-carboxylic acid with antiviral agent for treating hiv related neurological disorders
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512581A (en) * 1994-07-18 1996-04-30 Abbott Laboratories Iminoxycarboxylates and derivatives as inhibitors of leukotriene biosynthesis
GB9606805D0 (en) * 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
JP4427825B2 (ja) * 1997-07-24 2010-03-10 アステラス製薬株式会社 コレステロール低下作用を有する医薬組成物
IL136138A0 (en) * 1997-12-19 2001-05-20 Merck & Co Inc Arylthiazolidinedione derivatives
AR029876A1 (es) * 1998-05-11 2003-07-23 Takeda Pharmaceutical Compuesto de acido oxiiminoalcanoilo, composicion farmaceutica y agente para controlar receptores relacionados con retinoide que lo comprenden y su uso
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
CN1407969A (zh) * 1999-10-29 2003-04-02 武田药品工业株式会社 氧亚氨基链烷酸衍生物的制备方法

Also Published As

Publication number Publication date
EP1304121A4 (en) 2004-06-23
AU1303301A (en) 2001-06-06
CA2390932A1 (en) 2001-05-17
CN1423566A (zh) 2003-06-11
EP1304121A1 (en) 2003-04-23
KR20020060227A (ko) 2002-07-16
NO20022214L (no) 2002-07-09
WO2001034200A1 (fr) 2001-05-17
NO20022214D0 (no) 2002-05-08
US20050239854A1 (en) 2005-10-27
PL356745A1 (en) 2004-06-28

Similar Documents

Publication Publication Date Title
HUP0203837A2 (hu) Testtömegnövekedést gátló szerek
MY145080A (en) Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
BG106020A (en) Inhibitors of impdh enzyme
PL356252A1 (en) Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
DE602004007808D1 (de) Neue gamma secretase inhibitoren
DE60035032D1 (de) Verwendung von pioglitazone zur verbesserung der ketose und der azidose
CA2376497A1 (fr) Complexes metalliques de polyaminoacides bicycliques, leur procede de preparation et leur application en imagerie medicale
GB0225474D0 (en) Therapeutic agents
DE60332137D1 (en) Cyclohexyl-sulphone als gamma-sekretase-inhibitoren
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
ATE302753T1 (de) Sulfamide als gamma-secretase-inhibitoren
ZA200107450B (en) Dimeric compounds and their use as inhibitors of neuraminidase.
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
ATE396973T1 (de) Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit
ATE401314T1 (de) Benzodiazepin-derivate als gamma-secretase inhibitoren
EP1765335A4 (en) PYRAZOLAMIDE DERIVATIVES, COMPOSITIONS AND METHODS OF APPLYING THESE COMPOUNDS
AU2003223579A1 (en) Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
TR200102958T2 (tr) Siklooksijenaz-2 inhibitörleri olarak 4,5-diaril-3(2H)-furanon türevleri.
NO995932D0 (no) Anvendelse av tiazolidindion-derivater i behandling av polycystiske ovariesyndrom og svangerskapsdiabetes
MXPA05013733A (es) 2-aminobenzotiazoles como agonistas inversos del receptor de cb1.
HUP0400648A2 (hu) Ecteinascidin-743-t tartalmazó tumorellenes kezeléseknél alkalmazható készítmények
EE04278B1 (et) Pantoprasoolmagneesiumdihüdraat, seda sisaldav ravim ja selle kasutamine
RS51478B (sr) Upotreba bradikardijskih supstanci u lečenju miokardnih oboljenja povezanih sa hipertrofijom i nove kombinacije lekova
YU11402A (sh) Nova primena docetaksela za lečenje hepatoma

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees